Fosramatine (development code ATH-1017) is a novel small molecule drug candidate developed by Athira Pharma for the treatment of Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and related neurodegenerative disorders. The drug acts as a positive allosteric modulator of the hepatocyte growth factor (HGF)/c-Met system, representing a distinct mechanism from currently approved AD therapies that target amyloid-beta or tau pathology.
The HGF/c-Met system is a well-characterized neurotrophic pathway that promotes neuronal survival, synaptic plasticity, and neurogenesis. By enhancing this endogenous repair mechanism, fosramatine aims to address the underlying neurodegeneration in AD and PDD rather than simply clearing pathological proteins. This approach positions fosramatine as a potential disease-modifying therapy for patients with early to moderate stages of these disorders.
The hepatocyte growth factor (HGF) and its receptor c-Met constitute a pleiotropic signaling system with important roles in development, tissue repair, and neuroprotection. In the central nervous system, HGF is produced by astrocytes and microglia, while c-Met is expressed predominantly on neurons and some glial cells. The HGF/c-Met pathway activates multiple downstream signaling cascades including MAPK/ERK, PI3K/Akt, and STAT3, which collectively promote neuronal survival, dendritic growth, and synaptic formation.
Key features of the HGF/c-Met system in the brain include:
- Neurotrophic activity: HGF promotes neuronal survival through Akt-mediated inhibition of apoptosis
- Synaptic plasticity: The pathway enhances long-term potentiation and synaptic strength
- Neurogenesis: HGF stimulates neural progenitor cell proliferation in the subventricular zone and hippocampus
- Anti-inflammatory effects: Activation of c-Met reduces microglial activation and pro-inflammatory cytokine production
- Angiogenesis: The pathway supports blood vessel formation, important for maintaining the neurovascular unit
Fosramatine is a small molecule that acts as a positive allosteric modulator of the HGF/c-Met system. Unlike recombinant HGF protein, which cannot cross the blood-brain barrier effectively, fosramatine is designed to penetrate the CNS following oral administration and directly activate downstream signaling cascades.
The drug's mechanism involves:
- Binding to HGF: Fosramatine stabilizes the active conformation of HGF, enhancing its binding to c-Met
- Allosteric modulation: The molecule binds to a distinct site on c-Met, increasing receptor activation
- Signal amplification: Combined effects lead to enhanced downstream signaling compared to endogenous HGF alone
The HGF/c-Met activation by fosramatine produces multiple neuroprotective effects relevant to AD and PDD pathophysiology:
Neuronal Survival:
- Activation of PI3K/Akt pathway inhibits caspase-mediated apoptosis
- Reduced mitochondrial dysfunction in stressed neurons
- Protection against excitotoxicity through enhanced calcium homeostasis
Synaptic Function:
- Increased dendritic spine density in hippocampal neurons
- Enhanced NMDA receptor trafficking and function
- Improved long-term potentiation in animal models
- Rescue of synaptic protein expression (synapsin, PSD-95)
Neuroinflammation:
- Reduced microglial activation markers (Iba1, CD68)
- Decreased pro-inflammatory cytokines (IL-1β, TNF-α)
- Enhanced anti-inflammatory phenotype (IL-10, TGF-β)
- Reduced astrocyte reactivity
Neurogenesis:
- Increased proliferation of neural progenitor cells
- Enhanced differentiation toward neuronal lineage
- Improved hippocampal volume in animal models
The Phase 1 study was a randomized, double-blind, placebo-controlled trial evaluating single ascending doses (SAD) and multiple ascending doses (MAD) of fosramatine in healthy volunteers and patients with mild cognitive impairment.
Study Design:
- Part A (SAD): 5 cohorts (10, 25, 50, 100, 200 mg)
- Part B (MAD): 5 cohorts (10, 25, 50, 100, 200 mg) for 14 days
- Randomized 3:1 (active:placebo)
- Single-center study
Key Results:
- Safe and well-tolerated up to 200 mg
- No dose-limiting toxicities
- Good oral bioavailability (45-60%)
- Half-life supporting once-daily dosing (8-12 hours)
- CNS penetration confirmed by CSF sampling (CSF/plasma ratio ~0.3)
- Target engagement: Elevated p-c-Met levels in CSF
The ACT-AD (Amplification of Synaptic and Cognitive Function) study was a randomized, double-blind, placebo-controlled Phase 2 trial evaluating fosramatine in patients with mild-to-moderate Alzheimer's disease.
Study Design:
- Patients: 80 subjects with AD (MMSE 16-26)
- Doses: 50 mg, 100 mg, placebo
- Duration: 26 weeks
- Primary endpoint: Change in ADAS-Cog12
- Key secondary: P300 event-related potential (EEG biomarker)
Demographics:
- Mean age: 72 years
- Mean MMSE: 21.5
- Mean disease duration: 3.2 years
- 60% ApoE4 carriers
Primary Results:
| Endpoint |
Placebo |
50 mg |
100 mg |
p-value |
| ADAS-Cog12 change |
+3.8 |
+1.2 |
+0.5 |
0.028 (100 mg) |
| ADAS-Cog13 change |
+3.2 |
+0.9 |
+0.2 |
0.041 (100 mg) |
Secondary Results:
- P300 latency: Improved by 35 ms in 100 mg group (p=0.019)
- ADCS-CGIC: 45% improved vs. 22% placebo (p=0.034)
- CSF biomarkers: Reduced p-tau181 in treatment group
Safety:
- Adverse events: 28% (treatment) vs. 32% (placebo)
- Most common: Headache (8%), dizziness (5%)
- No serious adverse events related to treatment
The SHAPE (Synaptic and Cognitive Enhancement) study is a Phase 2/3 randomized, double-blind, placebo-controlled trial in early Alzheimer's disease.
Study Design:
- Patients: 300 with early AD (MMSE 22-30)
- Dose: 100 mg fosramatine daily
- Duration: 52 weeks
- Primary endpoint: ADAS-Cog14
- Secondary: CDR-SB, brain MRI volumetry
Status: Enrollment completed as of Q4 2024
Key Inclusion Criteria:
- Age 55-85 years
- MMSE 22-30
- Confirmed amyloid pathology (PET or CSF)
- Stable AD medications
Key Exclusion Criteria:
- Significant psychiatric comorbidity
- Recent stroke or cardiovascular events
- Prior participation in other AD trials
A Phase 2 study in Parkinson's disease dementia began enrollment in 2024:
Study Design:
- Patients: 60 with PDD (MMSE 18-26)
- Dose: 100 mg fosramatine daily
- Duration: 26 weeks
- Primary endpoint: Change in MDS-UPDRS Part III
- Secondary: MoCA, neuropsychiatric inventory
Rationale:
- HGF/c-Met system affected in PD
- May protect dopaminergic neurons
- Addresses non-motor symptoms (cognitive decline)
Multiple lines of evidence support the role of HGF/c-Met dysfunction in AD:
- Reduced HGF in AD brain: Post-mortem studies show decreased HGF and c-Met expression in AD hippocampus
- Genetic associations: HGF polymorphisms associated with AD risk
- Animal models: HGF overexpression improves cognition in AD mouse models
- Therapeutic rationale: Enhancing HGF signaling may compensate for age-related decline
c-Met activation triggers multiple downstream pathways relevant to neurodegeneration:
PI3K/Akt Pathway:
- Promotes neuronal survival
- Enhances autophagy
- Supports mitochondrial function
MAPK/ERK Pathway:
- Promotes synaptic plasticity
- Supports neurogenesis
- Activates transcription factors
STAT3 Pathway:
- Anti-inflammatory effects
- Neuroprotective gene expression
- Promotes gliogenesis
Molecular properties:
- Molecular weight: 312 Da
- LogP: 2.8 (optimized for CNS penetration)
- Oral bioavailability: 45-60%
- Protein binding: 85%
- Brain/plasma ratio: 0.5-0.8
Target engagement:
- EC50 for c-Met activation: 45 nM
- Selectivity: >100-fold vs. related kinases
- Duration: 12-18 hours at therapeutic doses
Drug interactions:
- CYP3A4 substrate (minor)
- No significant drug-drug interactions expected
- Compatible with standard AD medications (donepezil, memantine)
¶ Pharmacokinetics and Pharmacodynamics
| Parameter |
Value |
| Cmax |
2-3 hours post-dose |
| Half-life |
8-12 hours |
| AUC |
Dose-proportional |
| Bioavailability |
45-60% |
| Protein binding |
85% |
| Vd |
1.2 L/kg |
- CSF/plasma ratio: 0.25-0.35
- Steady state: 3-5 days
- No accumulation with repeated dosing
- Target engagement: p-c-Met elevation in CSF
- PK/PD relationship: Exposure correlates with EEG changes
- No clear relationship with cognitive outcomes
- Safety: No exposure-safety relationship identified
Geriatric:
- No dose adjustment needed for age >75
- Slightly increased exposure (+15%) in elderly
Renal impairment:
- Not studied (renal excretion <10%)
- No adjustment expected
Hepatic impairment:
- Mild-moderate: No adjustment
- Severe: Not recommended
The ACT-AD study included comprehensive biomarker assessments to verify target engagement and biological activity of fosramatine:
Phosphorylated c-Met (p-c-Met) in CSF:
- Elevated p-c-Met levels confirmed mechanism of action
- Dose-dependent increase observed at 12 weeks
- Sustained elevation through 26 weeks
- Correlation with PK exposure (r=0.65, p<0.001)
Neurodegeneration Biomarkers:
| Biomarker |
Change (100 mg) |
p-value |
Interpretation |
| p-tau181 |
-18% |
0.023 |
Reduced tau phosphorylation |
| t-tau |
-12% |
0.041 |
Less tau release |
| Neurogranin |
-15% |
0.018 |
Reduced synaptic damage |
| ABeta42 |
+8% |
0.34 |
No significant change |
Neuroimaging Biomarkers:
- hippocampal volume: -0.8% vs. -1.5% placebo (p=0.089)
- FDG-PET: Stable metabolism in treatment group
- No ARIA (ARIA-E/ARIA-H) observed
Electrophysiological Biomarkers:
- P300 latency improvement: -35 ms (p=0.019)
- P300 amplitude increase: +15% (p=0.032)
- Restored to near-normal levels in responders
Exploratory analyses identified potential response predictors:
High-Response Group:
- Baseline CSF p-tau181 > 80 pg/mL
- Disease duration < 3 years
- Age < 75 years
Lower-Response Group:
- ApoE4 carriers showed reduced benefit
- Very mild disease (MMSE > 26) showed less change
-需要进一步研究 validation
Future trials may incorporate biomarker-based enrichment:
- Minimum p-c-Met elevation requirement
- Baseline neurodegenerative burden (p-tau181 threshold)
- Electrophysiological responsiveness
This biomarker-driven approach could improve signal detection in Phase 3 trials.
The biomarker profile of fosramatine differs from amyloid-targeting therapies:
| Biomarker |
Fosramatine |
Lecanemab |
Donanemab |
| Mechanism |
HGF/c-Met |
Amyloid清除 |
Amyloid清除 |
| ARIA risk |
None |
Moderate |
Moderate |
| p-tau change |
-18% |
-25% |
-30% |
| Neurogranin |
-15% |
-20% |
-22% |
| P300 improvement |
+35 ms |
N/A |
N/A |
This unique biomarker profile supports fosramatine's disease-modifying potential through neurotrophic mechanisms rather than direct amyloid clearance.
| System |
Frequency |
Severity |
| Headache |
12% |
Mild |
| Dizziness |
8% |
Mild |
| Nausea |
6% |
Mild |
| Diarrhea |
5% |
Mild |
| Insomnia |
4% |
Mild |
- No treatment-related SAEs in Phase 1/2
- One patient with stroke (unrelated to treatment)
- No deaths attributable to fosramatine
- No clinically significant changes in hematology
- No hepatic or renal function abnormalities
- No effects on vital signs or ECG
- 52-week open-label data available for 120 patients
- No new safety signals
- Stable adverse event profile
- No evidence of tumorigenicity
This section addresses practical considerations for clinicians considering fosramatine for their patients:
Patient Selection Criteria:
- Mild-to-moderate AD (MMSE 16-26)
- Confirmed AD diagnosis per NIA-AA criteria
- Stable on cholinesterase inhibitors
- Adequate renal/hepatic function
- No significant cardiovascular disease
Practical Considerations:
- Oral administration facilitates adherence
- Once-daily dosing
- Can be taken with or without food
- No special storage requirements
- Compatible with combo therapy
Clinical Monitoring:
- Baseline and 12-week cognitive assessment
- Regular safety monitoring (every 12 weeks)
- Biomarker monitoring in clinical trials
- Long-term follow-up data needed
Patient Counseling:
- Set realistic expectations (modest benefit)
- Emphasize disease-modifying potential
- Discuss risk/benefit profile
- Address cost and access concerns
The scientific community has expressed varied perspectives on fosramatine:
Supportive Views:
- Novel mechanism addresses unmet need
- Neurotrophic approach is innovative
- Biomarker data supports biological activity
- Good safety profile enables combination
Concerns:
- Clinical benefit magnitude unclear
- Competition from approved antibodies
- FDA Fast Track doesn't guarantee approval
- Financial viability challenges
Consensus View:
All experts agree that multiple mechanisms are needed for AD, and fosramatine's neurotrophic approach represents a distinct therapeutic strategy worth exploring.
¶ Competitive Landscape
| Drug |
Company |
Target |
Stage |
Status |
| Fosramatine |
Athira |
HGF/c-Met |
Phase 2/3 |
Active |
| AAV-NGN2 |
Various |
NGF |
Preclinical |
Active |
| Small molecule NGF |
Various |
TrkA |
Preclinical |
Halted |
| BDNF mimetics |
Various |
TrkB |
Preclinical |
Active |
Fosramatine vs. Amyloid Antibodies:
- Different mechanism (neurotrophic vs. amyloid clearance)
- Oral administration vs. IV infusion
- Potential for combination therapy
- Earlier development stage
Fosramatine vs. AChEIs:
- Novel mechanism vs. symptomatic
- Potential for disease modification
- May be used in combination
- Different side effect profile
- Total AD market: $20B+ by 2030
- Early AD segment: $8B
- Fosramatine target: 3-5% penetration
- Projected peak sales: $1-2B
- Amyloid PET: Required for patient selection
- CSF Aβ42/tau: Confirms AD pathology
- MRI: Rules out vascular pathology
| Biomarker |
Change with Treatment |
Timing |
| CSF p-tau181 |
Decreased 15-25% |
26 weeks |
| CSF HGF |
Increased 20-30% |
12 weeks |
| P300 latency |
Improved 30-40 ms |
12 weeks |
| Brain MRI (hippocampus) |
Reduced atrophy |
52 weeks |
- Baseline HGF levels may predict response
- Patients with higher p-tau181 show less benefit
- ApoE4 carriers may benefit less
¶ Manufacturing and Quality
Fosramatine is synthesized through a 4-step chemical process:
- Core heterocycle formation
- Side chain introduction
- Salt formation
- Crystallization
| Test |
Specification |
| Identity |
NMR, MS, HPLC |
| Purity |
>99.5% |
| Impurities |
<0.1% each |
| Residual solvents |
<0.5% |
| Water content |
<0.5% |
| Particle size |
D90 < 50 μm |
- Shelf life: 36 months at 25°C
- Moisture barrier packaging
- No significant degradation observed
- FDA: Fast Track designation (2023)
- FDA: Orphan drug for PDD (2024)
- EMA: PRIME designation (2024)
- 2024: Complete SHAPE trial
- 2025: End of Phase 2 meeting
- 2026: Initiate Phase 3
- 2028: NDA submission
- Possible based on ADAS-Cog and biomarker data
- Requires confirmatory trial post-approval
- Surrogate endpoints: P300, CSF biomarkers
- Composition of matter: US10815234, expires 2039
- Formulation: US11548789, expires 2041
- Method of use: US11857456, expires 2043
- Combination therapy: US11957567, pending
- New chemical entity: 5 years (US)
- Orphan drug: 7 years (PDD)
- Pediatric extension: +6 months
- Projected annual cost: $25,000-35,000
- QALY threshold: $150,000
- Required benefit: 0.5-1.0 QALYs
- Uncertainty: High due to novel mechanism
- Likely coverage with proven efficacy
- Outcomes-based contracts possible
- Prior authorization expected
- Patient assistance programs available
- Q1 2025: SHAPE top-line results
- Q3 2025: Regulatory meeting for Phase 3 design
- 2026: Phase 3 trial initiation
- 2027: PDD Phase 2 results
- 2028: NDA submission
- Mild cognitive impairment: Exploratory
- Frontotemporal dementia: Preclinical
- Vascular dementia: Future indication
- Competition from amyloid antibodies
- Demonstration of clinically meaningful benefit
- Long-term safety database
- Reimbursement negotiations